Clinical Overview

Left ventricular high voltage (LVHV) is a strictly electrical label: a QRS complex whose amplitude crosses a defined voltage threshold — Sokolow-Lyon, Cornell, or a related criterion — on the surface ECG. It is not an anatomic diagnosis. This is the single most important distinction on this page. LVHV is not the same concept as Left Ventricular Hypertrophy (LVH), a separate condition on this platform describing an actual increase in left ventricular myocardial mass confirmed by echocardiography or cardiac MRI (StatPearls, 2026). A strip can carry the LVHV finding while the myocardium underneath is completely normal, and a myocardium that is genuinely hypertrophied can fail to produce a QRS that crosses any voltage threshold. The two ideas are related but not interchangeable, and this page exists precisely because the voltage pattern by itself is a weak, non-specific signal that is frequently over-read as if it were the anatomic diagnosis.

The classical assumption behind any voltage criterion is that thicker myocardium generates a stronger electrical field, pushing the leftward and posterior QRS forces higher and producing a taller R wave in the lateral leads and a deeper S wave in the right precordial leads. The 2023 ISE/ISHNE expert consensus statement is explicit that this assumption does not hold up well in practice: the low sensitivity of voltage criteria as a marker of true left ventricular mass has been repeatedly documented, and increased QRS amplitude is present in only a minority of patients who actually have anatomic hypertrophy (Bacharova et al., Annals of Noninvasive Electrocardiology, 2024). The corollary — the reason this page needs to exist as its own entry — is that the amplitude threshold can also be crossed by hearts that are not hypertrophied at all.

Body habitus is one of the clearest non-hypertrophy drivers of QRS amplitude. Adipose tissue between the myocardium and the recording electrode attenuates the electrical signal reaching the skin surface, so a higher body mass index measurably reduces recorded QRS voltage; the converse is equally true — a leaner chest wall with less attenuating tissue records a higher voltage for the same underlying myocardium (Obesity Science & Practice, 2025). A voltage criterion was never designed to correct for this, so a thin patient with an entirely normal left ventricle can cross a threshold that a heavier patient with genuine hypertrophy does not.

Age, sex, and athletic conditioning add further non-hypertrophy variance. In a retrospective cohort of 9,254 young athletes aged 12-35, amplitude-based voltage criteria for LVH were found to generate false positives often enough that the authors proposed separate, higher thresholds by sex — a 99th-percentile Sokolow-Lyon score above 6.8 mV for males and above 4.7 mV for females — specifically to reduce the false-positive burden the traditional, single threshold produces in this population (Montalvo et al., Heart Rhythm, 2026). The 2017 international consensus statement on athlete ECG interpretation lists “isolated QRS voltage criteria for left or right ventricular hypertrophy” — voltage alone, with no accompanying repolarization change, chamber enlargement, or axis abnormality — among the normal training-related ECG findings that require no further evaluation in an athlete (Sharma et al., Journal of the American College of Cardiology, 2017), a classification a 2024 case report of a lifelong endurance athlete’s ECG cites and applies directly (Diaz-Rodriguez et al., Cureus, 2024). An earlier study of screening criteria in athletes reached the same practical conclusion, that isolated R and S wave amplitudes exceeding traditional LVH thresholds are better read as a physiological response to sustained exercise than as pathology (Singla et al., Journal of Electrocardiology, 2015), and a comparison of male and female athletes’ ECGs found isolated QRS voltage criteria met by the Sokolow-Lyon index substantially more often in men — a sex difference in normal voltage, not a sex difference in disease prevalence (Corîci et al., Current Health Sciences Journal, 2018).

None of this means an LVHV finding is always benign. When the same voltage threshold is crossed in an older patient, a patient with hypertension or known structural heart disease, or a tracing that also shows the strain pattern (lateral ST depression with T wave inversion), left atrial abnormality, or QRS broadening, the finding carries the same weight it does on the LVH page and should be worked up the same way. The clinical question this label should always prompt is which of those two situations is in front of you — an isolated voltage finding in a young, lean, or well-trained person, or a voltage finding accompanying other markers of a genuinely remodeled heart — and the ECG alone, at the level of a single criterion, cannot answer that question. Echocardiography remains the test that establishes or excludes true LVH, defined as a left ventricular mass index above 115 g/m² in men and above 95 g/m² in women (StatPearls, 2026).

LVHV produces no symptoms of its own; it is an amplitude measurement, not a physiologic derangement. Whether a patient is symptomatic depends entirely on what, if anything, is actually happening structurally. A young athlete with isolated LVHV and a structurally normal heart is asymptomatic by definition. A patient in whom the voltage finding reflects true underlying hypertrophy may report dyspnea, chest pain, palpitations, syncope, or exercise intolerance as that underlying process progresses (StatPearls, 2026).

Contributors to a high-voltage QRS fall into two groups that this page deliberately keeps separate. Non-hypertrophic contributors — the ones that make LVHV its own finding rather than a synonym for LVH — include thin or lean body habitus, younger age, male sex, and athletic training without pathological remodeling (Obesity Science & Practice, 2025; Montalvo et al., 2026; Sharma et al., 2017; Singla et al., 2015; Corîci et al., 2018). Contributors that raise genuine suspicion for anatomic hypertrophy underneath the voltage finding are the same ones that cause LVH: hypertension, aortic stenosis, aortic or mitral regurgitation, hypertrophic cardiomyopathy, chronic kidney disease, obesity-associated remodeling, and infiltrative disease (StatPearls, 2026). A conduction abnormality complicates the picture further: in a Taiwanese cohort of 431 adults, traditional voltage criteria performed with low sensitivity but high specificity overall, and their diagnostic performance dropped substantially in patients with complete right bundle branch block, particularly for criteria built on the anteroseptal leads — QRS duration correlated with left ventricular mass better than voltage did in that setting (Ou Yang and Wu, Journal of Electrocardiology, 2026). A voltage criterion applied in that setting is unreliable in either direction.

Interpretation Guide

Key Features:

• Rate: not a defining feature — LVHV is a QRS amplitude finding superimposed on whatever rate accompanies it
• Rhythm: not a defining feature — the finding is read against an underlying supraventricular rhythm and says nothing about impulse origin
• P waves: within normal limits unless a coexisting chamber abnormality is present; a left atrial abnormality alongside the voltage finding shifts the picture toward true LVH rather than isolated LVHV
• PR interval: within normal limits unless a separate, coexisting AV conduction abnormality is present
• QRS complex: the entire finding. Whichever criterion is applied, the amplitude simply crosses a defined threshold — nothing about QRS morphology, axis, or duration is required to be abnormal. Sokolow-Lyon: S wave in V1 plus R wave in V5 or V6 above 35 mm (StatPearls, 2026; Karagöz et al., Turkish Society of Cardiology Archives, 2024). Cornell voltage: R wave in aVL plus S wave in V3, above 28 mm in men and above 20 mm in women (StatPearls, 2026; Karagöz et al., 2024). Cornell product: the Cornell voltage sum, adding 8 mm for women, multiplied by QRS duration, above 2440 mm·ms (Karagöz et al., 2024). Every threshold is a millimetre measurement of the printed tracing, so confirm standard calibration before applying any of them — a tracing at half standard gain halves every amplitude. A normal QRS duration and a normal axis are expected in isolated LVHV; if either is abnormal, look harder for a cause other than voltage alone
• ST segment: within normal limits in isolated LVHV. Downsloping, convex ST depression in the lateral leads (the strain pattern) is not part of the voltage criterion and, when present alongside it, points toward true anatomic LVH rather than an isolated voltage finding (Bacharova et al., 2024)
• T waves: within normal limits in isolated LVHV, for the same reason. Lateral T wave inversion accompanying a voltage criterion is a second, independent finding that argues against reading the tracing as benign isolated LVHV
• QT interval: not part of any voltage criterion and not independently affected by LVHV
• Other findings: document the patient’s age, sex, body habitus, and athletic history alongside the finding — every source above shows these change how the same measured voltage should be interpreted far more than the specific millimetre value does. Check for complete right bundle branch block before applying any threshold; its presence degrades the accuracy of voltage criteria substantially, particularly criteria built on the anteroseptal leads (Ou Yang and Wu, 2026)

Key Leads

• Leads V1, V2, V3 – The right precordial half of the measurement: the S wave that feeds the Sokolow-Lyon and Cornell criteria. An equivocal or poorly recorded electrode here changes the arithmetic directly (StatPearls, 2026; Karagöz et al., 2024)
• Lead aVL – Carries the R wave used by Cornell voltage and the Cornell product (StatPearls, 2026; Karagöz et al., 2024)
• Leads V5 and V6 – The leftward half of the measurement: the tall R wave that supplies the second term of Sokolow-Lyon (StatPearls, 2026)
• Leads I, aVL, V5, V6 read together – Not part of the voltage criteria themselves, but the leads to check for the strain pattern before accepting a tracing as isolated, benign LVHV. Downsloping ST depression with T wave inversion here means the tracing is carrying a second finding beyond voltage, and the differential shifts toward true anatomic hypertrophy (Bacharova et al., 2024)

Differential Diagnosis

• Left Ventricle Hypertrophy (LVH) — the anatomic diagnosis this finding is most often confused with. Distinguishing clue: LVH requires echocardiographic or cardiac MRI confirmation of increased left ventricular mass; LVHV is only a voltage threshold on the surface ECG. A strip meeting a voltage criterion plus the strain pattern, left atrial abnormality, or QRS broadening reads as consistent with true LVH — an isolated voltage crossing in an otherwise normal tracing, especially in a young, lean, or well-trained patient, reads as isolated LVHV and should not be reported as the anatomic diagnosis.
• Right Ventricle Hypertrophy (RVH) — the opposite chamber and the opposite precordial pattern. Distinguishing clue: RVH shifts forces rightward and anteriorly, producing a dominant R wave in V1 and right axis deviation, whereas LVHV involves a deep S wave in V1 with a tall R in V5-V6. The two are measured with different criteria and should not be conflated when the tall-R-wave pattern sits in the wrong leads for LVHV.
• Lower Voltage QRS In All Lead (LVQRSAL) — the informative opposite pattern. Distinguishing clue: where LVHV is a voltage threshold crossed upward, LVQRSAL is diffusely low QRS amplitude across all leads, classically raising concern for an infiltrative process, pericardial effusion, or another cause of signal attenuation rather than for hypertrophy at all. The two labels sit at opposite ends of the same amplitude spectrum.
• Complete Right Bundle Branch Block (CRBBB) — a conduction abnormality that measurably degrades the accuracy of every voltage criterion, especially those built on the anteroseptal leads. Distinguishing clue: a QRS at or above 120 ms with an rSR’ pattern in V1 identifies CRBBB; once identified, a voltage criterion applied on top of it is far less reliable in either direction, and QRS duration correlates with left ventricular mass better than voltage does in that setting (Ou Yang and Wu, 2026).

Treatment Brief

The voltage finding itself is not treated. What a monitoring technician or nursing student owns here is recognizing that LVHV is a threshold crossing, not a diagnosis, and documenting enough context for a clinician to interpret it correctly.

• Confirm standard calibration and correct lead placement before accepting any voltage measurement. Every threshold is a millimetre reading, so a non-standard gain setting or a misplaced precordial electrode changes the answer without changing the patient.
• State which criterion was met and the measured values, not just the label “LVHV” or “abnormal ECG” — the criteria use different leads and thresholds and are not interchangeable (Karagöz et al., 2024).
• Record the patient’s age, sex, body habitus, and athletic history alongside the finding. These factors materially change how the same measured voltage should be read, more than any additional millimetre of amplitude does (Obesity Science & Practice, 2025; Montalvo et al., 2026; Sharma et al., 2017).
• Check for the strain pattern, left atrial abnormality, and QRS broadening before deciding how concerning the finding is. Voltage alone, with none of those accompanying features, is the pattern athlete-ECG guidance treats as a normal training-related finding requiring no further evaluation (Sharma et al., 2017; Diaz-Rodriguez et al., 2024).
• Check for complete right bundle branch block before applying any threshold; its presence degrades voltage-criteria accuracy substantially and the finding should not be over-read in that setting (Ou Yang and Wu, 2026).
• Do not read an isolated voltage finding as ruling in — or a normal voltage as ruling out — anatomic hypertrophy. Voltage criteria have documented low sensitivity for true left ventricular mass in either direction; echocardiography is what establishes or excludes the diagnosis (Bacharova et al., 2024; StatPearls, 2026).
• Escalate to the provider when the voltage finding is new, is accompanied by symptoms, or appears alongside other ECG markers of chamber enlargement — the same threshold that is unremarkable in a young athlete is not automatically unremarkable in an older or hypertensive patient.